Is Ki67 a marker for the transformation of laryngeal dysplasia to carcinoma?

Acta Oto-Laryngologica

Volumn 126, Issue 4, 2006, Pages 418-421

  Mirza, S ^a,c   Jeannon, J P ^a   Soames, J ^b   Wilson, J A ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Carcinoma; Dysplasia; Ki67; Larynx

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; DYSPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MICROLARYNGOSCOPY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33646347433     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480500416785     Document Type: Article

References (14)

1. Sternernsen TC, Hoel PS, Boysen M. Carcinoma in situ of the larynx: an evaluation of its natural clinical course. Clin Otol 1991;16:358-63.
2. Cuchi A, Bombi JA, Avellaneda R, Cardessa A, Traserra J. Precancerous lesions of the larynx: clinical and pathologic correlations and prognostic aspects. Head Neck 1994;16: 545-9.
3. Blackwell KE, Calcaterra TC, Fu YS. Laryngeal dysplasia. Epidemiology and treatment outcome. Ann Otol Rhinol Laryngol 1995;104:596-602.
4. Plch J, Par I, Navratilova I, Blahova M, Zavadil M. Long term follow-up study of laryngeal precancer. Auris Nasus Larynx 1998;25:407-12.
5. Papadimitrakopoulou VA, Clayman GL, Shin DM. Biochemo-prevention for dysplastic lesions of the upper aero-digestive tract. Arch Otolaryngol Head Neck Surg 1999;125: 1083-9.
6. Hirano M, Sato K. Laser surgery for epithelial hyperplasia of the vocal fold. Ann Otol Rhinol Laryngol 1993;102:85-91.
7. Blackwell KE, Fu YS, Calcaterra TC. Laryngeal dysplasia. A clinicopathologic study. Cancer 1995;75:457-63.
8. Pignataro LD, Broichi G, Lavezzi A, Biondo B, Ottaviani F. PCNA - a cell proliferation marker in vocal chord cancer. Part I: Premalignant laryngeal lesions. Anticancer Res 1995; 15:1517-20.
9. Uhlman DL, Adams G, Knapp D, Aeppli DM, Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res 1996;56:2199-205.
10. Gallo O, Franchi A, Chiarelli I, Porfirio B, Grande A, Simonetti L, et al. Potential biomarkers in predicting progression of epithelial hyperplastic lesions of the larynx. Acta Otolaryngol Suppl 1997;527:30-8.
11. Pignataro L, Capaccio P, Pruneri, Carboni N, Buffa R, Neri A, et al. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx. J Laryngol Otol 1998;112: 455-9.
12. Jeannon J-P, Soames JV, Wilson JA. Molecular markers in dysplasia of the larynx: expression of cyclin-dependent kinase inhibitors p21 and p27, and p53 tumour suppressor gene in predicting cancer risk. Clin Otol 2003;28:552-8.
13. Silvestri F, Bussani R, Pavletic N, Mannone T, Bosatra A. From epithelial dysplasia to squamous carcinoma of the head and neck region: evolutive and prognostic histopathological markers. Acta Otolaryngol Suppl 1997;527:49-51.
14. Blanquez MJ, Regadera J, Marino J, Newman RE, Notario V. Gradual deregulation and loss of PCPH expression in the progression of human laryngeal neoplasia. Mol Carcinog 2002;35:186-95.